Last Update 30 Oct 25
Encompass Health's analyst price target has been increased by $10 to $150. Analysts cite strong discharge growth and ongoing expansion strategies as key factors supporting the upward revision.
Analyst Commentary
Analyst sentiment following the price target raise for Encompass Health reflects both optimism and caution regarding the company's growth trajectory and valuation.
Bullish Takeaways
- Bullish analysts point to continued strong discharge growth as a key factor supporting the revised valuation.
- Execution of the de novo strategy, particularly targeting new markets with historically low conversion rates of acute care discharges to inpatient rehabilitation facilities (IRFs), is expected to drive further expansion.
- Ongoing efforts to improve conversion rates at existing hospitals could enhance overall operational efficiency and revenue growth.
- Plans to convert beds from semi-private to private are seen as a positive move. This change could potentially increase patient satisfaction and optimize hospital capacity.
Bearish Takeaways
- Some bearish analysts express concern about the challenges of sustaining strong discharge growth in a competitive healthcare environment.
- There are potential risks associated with the execution of new market entry strategies, particularly in regions with low historical conversion rates.
- Operational changes, such as converting beds from semi-private to private, could lead to increased costs and temporary disruptions during implementation.
What's in the News
- Opened the 25th Encompass Health Rehabilitation Hospital in Florida, located in St. Petersburg. The facility offers 50 private rooms and advanced rehabilitation services for patients recovering from various conditions (Key Developments).
- Launched the first Encompass Health facility in Connecticut, a 40-bed hospital in Danbury that provides comprehensive inpatient rehabilitation for conditions such as strokes and orthopedic injuries (Key Developments).
- Announced a joint venture with BSA Health System to operate a new 50-bed rehabilitation hospital in Amarillo, Texas. Opening is planned for late 2025 (Key Developments).
- Plans to construct a 50-bed inpatient rehabilitation hospital in Haslet, Texas, as part of ongoing national expansion efforts (Key Developments).
- Raised 2025 earnings guidance with higher net operating revenue expectations, reflecting improved business outlook (Key Developments).
Valuation Changes
- Fair Value Estimate remains unchanged at $139.08 per share.
- Discount Rate holds steady at 6.78%, indicating no change in risk assessment.
- Revenue Growth forecast has edged down fractionally to 8.14% from 8.14%.
- Net Profit Margin is virtually flat, moving marginally up to 9.93% from 9.92%.
- Future P/E Ratio estimate remains constant at 23.80x.
Key Takeaways
-  Demographic shifts and strategic expansions are fueling strong demand, differentiated growth, and market outperformance for the company's core inpatient rehabilitation services.
-  Investments in technology, partnerships, and diversified payer streams are enhancing operational efficiency, financial resilience, and long-term revenue and margin prospects.
- Operating challenges from labor shortages, regulatory risks, and disruptive care models threaten profitability, while heavy capital spending and tech disruption could constrain growth and margins.
Catalysts
About Encompass Health- Provides post-acute healthcare services in the United States and Puerto Rico.
-  The surge in the 65-plus population and persistent undersupply of inpatient rehabilitation beds are driving high and still-unmet demand for Encompass Health's core services; ongoing hospital openings and bed expansions position the company to capture significant incremental patient volume, supporting higher revenue growth for years to come.
-  Growth in admissions from complex neurological, stroke, and brain injury cases-closely linked to rising chronic disease prevalence-reinforces Encompass Health's outperformance in medically complex care, which differentiates it from competitors and should bolster both top-line and margins through payer mix improvement and potentially higher reimbursement rates.
-  Partnerships with managed care organizations and the growing VA Community Care Network are expanding referral streams and managed care pricing (with mid-teens growth), adding payer diversification and insulating revenue from public reimbursement volatility.
-  Encompass Health's ongoing investment in AI-driven workflow optimization and predictive analytics is already improving clinical quality/outcomes and employee efficiency, which supports both patient/provider satisfaction and operational margin improvement over time.
- Sustained execution of the company's high-return de novo hospital and bed addition strategy, combined with a robust pipeline in underserved/new markets (and CON relaxation in key states), is set to drive outsized same-store and total discharge growth, translating to accelerating revenue and EBITDA expansion relative to market expectations.
Encompass Health Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Encompass Health's revenue will grow by 8.1% annually over the next 3 years.
- Analysts assume that profit margins will increase from 9.2% today to 9.9% in 3 years time.
- Analysts expect earnings to reach $711.6 million (and earnings per share of $6.46) by about September 2028, up from $522.4 million today.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 23.2x on those 2028 earnings, down from 24.2x today. This future PE is greater than the current PE for the US Healthcare industry at 21.0x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.
Encompass Health Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?-  Encompass Health faces persistent labor market pressures, including ongoing nursing, therapy, and physician shortages; while management has seen some improvements in hiring and retention, these challenges could cause wage inflation, higher turnover, and capacity constraints, ultimately squeezing net margins and limiting long-term earnings growth.
-  The company is investing heavily in de novo facilities and bed expansions to capture growth, leading to elevated capital expenditure requirements and preopening ramp-up costs; if demand fails to materialize fully or costs overrun, this could compress free cash flow and reduce returns on invested capital, impacting both earnings and future capital deployment flexibility.
-  Encompass Health remains highly dependent on Medicare and other government reimbursement, as shown by focus on CMS rules and updates; regulatory changes, including potential rate cuts, heightened audit scrutiny, or policy shifts toward alternative care models, pose significant risks to revenue stability and profitability.
-  The accelerating industry shift toward value-based care and outpatient/home-based rehabilitation models threatens the long-term relevance of inpatient rehabilitation facilities, exposing Encompass Health to risks of declining patient volumes and reduced market share, thereby negatively affecting revenue growth.
- Although Encompass Health is leveraging AI and technology for clinical efficiency, rapid technological advancements may enable competitors or disrupt the traditional inpatient rehab setting (for example, through telemedicine or advanced at-home rehab solutions), risking structural headwinds that could erode both revenues and net margins over the longer term.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $135.75 for Encompass Health based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $7.2 billion, earnings will come to $711.6 million, and it would be trading on a PE ratio of 23.2x, assuming you use a discount rate of 6.8%.
- Given the current share price of $125.29, the analyst price target of $135.75 is 7.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

